Advanced NSCLC Without Driver Mutation: Treatment Landscape in Malaysia
Dr Nurhayati Mohd Marzuki, Institut Perubatan Respiratori

Lung cancer is one of the most common cancers in Malaysia. 90 percent of patients present with Stage III or IV disease. Lung cancer patients in Malaysia have one of the poorest survival rates compared to other cancers.

Multiple factors contributed to the survival rate, i.e., late presentation, stigma and perception among others. Available therapy nevertheless is one of the most important factors for survival.
Health care system in Malaysia is divided by the economic margin: and public and private healthcare. Accessibility to innovative drugs is limited. An out of the box solution must be sought to improve the accessibility which leads to better outcome.